{"id":457319,"date":"2021-03-15T07:03:38","date_gmt":"2021-03-15T11:03:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457319"},"modified":"2021-03-15T07:03:38","modified_gmt":"2021-03-15T11:03:38","slug":"marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/","title":{"rendered":"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n HOUSTON<\/span>, March 15, 2021<\/span> \/PRNewswire\/ —\u00a0Marker Therapeutics, Inc.<\/a><\/u>\u00a0(NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang<\/span>, will present at the upcoming Virtual\u00a0Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021<\/span> at 3:10 p.m. ET<\/span>.<\/p>\n

\n

\n
\n \"Marker
\n <\/a>\n <\/p>\n<\/p><\/div>\n

A live webcast of the presentation will be accessible from the Investors section of the company’s website at markertherapeutics.com<\/a>\u00a0and will be available for replay following the event.<\/p>\n

\n About Marker Therapeutics, Inc.
<\/b>Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.<\/p>\n

To receive future press releases via email, please visit: https:\/\/www.markertherapeutics.com\/email-alerts<\/a>.<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference-301246974.html<\/a><\/p>\n

SOURCE Marker Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire HOUSTON, March 15, 2021 \/PRNewswire\/ —\u00a0Marker Therapeutics, Inc.\u00a0(NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual\u00a0Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m. ET. A live webcast of the presentation will be accessible from the Investors section of the company’s website at markertherapeutics.com\u00a0and will be available for replay following the event. About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor … <\/p>\n

Continue reading “Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457319","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMarker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire HOUSTON, March 15, 2021 \/PRNewswire\/ —\u00a0Marker Therapeutics, Inc.\u00a0(NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual\u00a0Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m. ET. A live webcast of the presentation will be accessible from the Investors section of the company’s website at markertherapeutics.com\u00a0and will be available for replay following the event. About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor … Continue reading "Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T11:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/771253\/Marker_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference\",\"datePublished\":\"2021-03-15T11:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"wordCount\":296,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/771253\\\/Marker_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/\",\"name\":\"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/771253\\\/Marker_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-03-15T11:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/771253\\\/Marker_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/771253\\\/Marker_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","og_description":"PR Newswire HOUSTON, March 15, 2021 \/PRNewswire\/ —\u00a0Marker Therapeutics, Inc.\u00a0(NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual\u00a0Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m. ET. A live webcast of the presentation will be accessible from the Investors section of the company’s website at markertherapeutics.com\u00a0and will be available for replay following the event. About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor … Continue reading \"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T11:03:38+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/771253\/Marker_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference","datePublished":"2021-03-15T11:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/"},"wordCount":296,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/771253\/Marker_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/","name":"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/771253\/Marker_Therapeutics_Logo.jpg","datePublished":"2021-03-15T11:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/771253\/Marker_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/771253\/Marker_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457319"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457319\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}